The US Patent and Trademark Office has granted Cognition Therapeutics protection through 2045 for a crystalline polymorph of zervimesine (CT1812), an investigational once-daily oral therapy, covering composition of matter, manufacturing process and therapeutic use in Alzheimer's disease, dementia with Lewy bodies and dry age-related macular degeneration. The company plans to finalize registrational endpoints with the FDA for dementia with Lewy bodies and begin manufacturing the new crystalline form in early 2027. The patent extends commercial exclusivity well beyond the typical window for a compound still in Phase 2 development.
Key Points
- Zervimesine polymorph patented to 2045, extendable five years post-approval
- Phase 2 signals in Lewy body dementia and Alzheimer's disease
- Registrational manufacturing targeted for first quarter of 2027
Longevity Analysis
Zervimesine targets the sigma-2 receptor pathway implicated in how neurons handle toxic protein oligomers, placing it among the interventions aimed at protecting synaptic integrity rather than clearing plaque alone. Its parallel investigation in dry age-related macular degeneration points to shared degenerative mechanisms across neural and retinal tissue, where cellular clearance and repair capacity decline together with age. Intellectual property runway matters here because neurodegeneration trials require long observation windows, and sustained funding determines whether a mechanism reaches the clinic at all.
Original published by LT Wire.